Bafna Pharma.

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "125.94",
    "chg": 5.44,
    "chgp": "4.51%",
    "dir": 1,
    "prev_price": "120.50",
    "mcapval": "296.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE878I01022",
    "curr_date": "Mar 20",
    "curr_time": "",
    "bse_nse_vol": "11.52 k",
    "exc_status": "Active",
    "traded_date": "Mar 20, 2026",
    "traded_date_str": "2026 03 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Gains 27.46%: 6 Key Factors Driving the Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-gains-2746-6-key-factors-driving-the-surge-3905348",
        "imagepath": "",
        "date": "2026-03-21 15:04:33",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Mar:</strong> Downgrade to Strong Sell; stock hits upper circuit at Rs.104.11 (+4.99%)</p>\n                    <p><strong>17 Mar:</strong> Upper circuit hit again at Rs.109.31 (+4.99%) with rising delivery volumes</p>\n                    <p><strong>18 Mar:</strong> Third consecutive upper circuit close at Rs.114.77 (+4.99%) amid volatile trading</p>\n                    <p><strong>19 Mar:</strong> Fourth upper circuit close at Rs.119.15 (+4.89%) with increased investor participation</p>\n                    <p><strong>20 Mar:</strong> Fifth consecutive upper circuit close at Rs.125.10 (+4.99%) with strong delivery volume surge</p>\n                </div>\n\n                <div clas..."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3903008",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3903008.png",
        "date": "2026-03-20 11:00:08",
        "description": "At Rs 126.52, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 19 Mar 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-momentum-3900059",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3900059.png",
        "date": "2026-03-19 10:00:13",
        "description": "Bafna Pharmaceuticals Ltd (Stock ID: 852453) surged to its upper circuit limit on 19 Mar 2026, closing at ₹120.5, marking a maximum daily gain of 4.99%. This sharp rally was driven by robust buying interest, with the stock outperforming its sector and broader market indices despite a subdued market environment."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3898425",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3898425.png",
        "date": "2026-03-18 10:00:17",
        "description": "Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 18 Mar 2026, reflecting robust buying interest and a maximum daily gain of 4.99%. The micro-cap pharmaceutical stock outperformed its sector and broader market indices, signalling renewed investor enthusiasm despite its Strong Sell mojo grade."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3896134",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3896134.png",
        "date": "2026-03-17 10:00:13",
        "description": "Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 17 Mar 2026, reflecting robust investor demand and significant buying momentum. The stock closed at ₹109.31, marking a maximum daily gain of 4.99%, outperforming its sector and broader market indices amid heightened trading activity and regulatory freeze on further price movement."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3894282",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3894282.png",
        "date": "2026-03-16 15:00:07",
        "description": "Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 16 Mar 2026, registering a maximum daily gain of 4.99% to close at ₹104.11. This sharp rally was driven by robust buying interest despite the stock opening with a gap down, signalling a notable reversal after three consecutive days of decline in a challenging micro-cap pharmaceuticals sector."
      },
      {
        "title": "Bafna Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-downgraded-to-strong-sell-amid-technical-and-financial-weakness-3892860",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_mojoScore_3892860.png",
        "date": "2026-03-16 08:12:12",
        "description": "Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 March 2026, reflecting deteriorating technical indicators and stagnant financial performance. Despite a modest one-year stock return outperforming the broader market, the company faces significant challenges across quality, valuation, financial trends, and technical parameters that have prompted a reassessment of its investment appeal."
      },
      {
        "title": "Bafna Pharmaceuticals Drops 12.21%: Death Cross and Lower Circuit Mark a Bearish Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-drops-1221-death-cross-and-lower-circuit-mark-a-bearish-week-3891060",
        "imagepath": "",
        "date": "2026-03-14 13:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Mar 09:</strong> Lower circuit hit amid heavy selling pressure (Rs.106.59)</p>\n                    <p><strong>Mar 13:</strong> Death Cross formation signalling bearish trend (Rs.98.15)</p>\n                    <p><strong>Week Close:</strong> Rs.98.15 (-12.21%) vs Sensex (-4.87%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.111.80</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.98.15</div><div class=\"stat-change negative\">-12.21%</div></div>\n                    <div class=\"stat-it..."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Forms Death Cross, Signalling Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-forms-death-cross-signalling-bearish-trend-ahead-3889962",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_dealthcross_3889962.png",
        "date": "2026-03-13 19:00:24",
        "description": "Bafna Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s long-term strength amid ongoing sector challenges."
      }
    ],
    "total": 286,
    "sid": "852453",
    "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "details": "Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 13, 2019.",
      "source": "NSE",
      "caption": "Bafna Pharmaceuticals Limited - Outcome of Board Meeting",
      "datetime": "14-Nov-2019"
    },
    {
      "details": " <table><tr><td>The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. </td></tr></table>",
      "source": "NSE",
      "caption": "Reply to Clarification- Financial results",
      "datetime": "27-Aug-2019"
    },
    {
      "details": " <table><tr><td>BAFNAPHARM: Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital. </td></tr></table>",
      "source": "NSE",
      "caption": "Suspension of trading in equity shares",
      "datetime": "21-Aug-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Gains 27.46%: 6 Key Factors Driving the Surge

2026-03-21 15:04:33

Key Events This Week

16 Mar: Downgrade to Strong Sell; stock hits upper circuit at Rs.104.11 (+4.99%)

17 Mar: Upper circuit hit again at Rs.109.31 (+4.99%) with rising delivery volumes

18 Mar: Third consecutive upper circuit close at Rs.114.77 (+4.99%) amid volatile trading

19 Mar: Fourth upper circuit close at Rs.119.15 (+4.89%) with increased investor participation

20 Mar: Fifth consecutive upper circuit close at Rs.125.10 (+4.99%) with strong delivery volume surge

Read full news article

Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent

2026-03-20 11:00:08

At Rs 126.52, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 19 Mar 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Momentum

2026-03-19 10:00:13

Bafna Pharmaceuticals Ltd (Stock ID: 852453) surged to its upper circuit limit on 19 Mar 2026, closing at ₹120.5, marking a maximum daily gain of 4.99%. This sharp rally was driven by robust buying interest, with the stock outperforming its sector and broader market indices despite a subdued market environment.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-03-18 10:00:17

Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 18 Mar 2026, reflecting robust buying interest and a maximum daily gain of 4.99%. The micro-cap pharmaceutical stock outperformed its sector and broader market indices, signalling renewed investor enthusiasm despite its Strong Sell mojo grade.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-03-17 10:00:13

Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 17 Mar 2026, reflecting robust investor demand and significant buying momentum. The stock closed at ₹109.31, marking a maximum daily gain of 4.99%, outperforming its sector and broader market indices amid heightened trading activity and regulatory freeze on further price movement.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-03-16 15:00:07

Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 16 Mar 2026, registering a maximum daily gain of 4.99% to close at ₹104.11. This sharp rally was driven by robust buying interest despite the stock opening with a gap down, signalling a notable reversal after three consecutive days of decline in a challenging micro-cap pharmaceuticals sector.

Read full news article

Bafna Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Weakness

2026-03-16 08:12:12

Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 March 2026, reflecting deteriorating technical indicators and stagnant financial performance. Despite a modest one-year stock return outperforming the broader market, the company faces significant challenges across quality, valuation, financial trends, and technical parameters that have prompted a reassessment of its investment appeal.

Read full news article

Bafna Pharmaceuticals Drops 12.21%: Death Cross and Lower Circuit Mark a Bearish Week

2026-03-14 13:00:05

Key Events This Week

Mar 09: Lower circuit hit amid heavy selling pressure (Rs.106.59)

Mar 13: Death Cross formation signalling bearish trend (Rs.98.15)

Week Close: Rs.98.15 (-12.21%) vs Sensex (-4.87%)

Week Open

Rs.111.80

Week Close

Rs.98.15

-12.21%

Read full news article

Bafna Pharmaceuticals Ltd Forms Death Cross, Signalling Bearish Trend Ahead

2026-03-13 19:00:24

Bafna Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s long-term strength amid ongoing sector challenges.

Read full news article

View All News